{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling that primes tumors for improved response to immune checkpoint blockade.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely, and mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination induces a broader peptide repertoire display on MHC-I, enhancing tumor visibility to T cells and increasing CD8+ T-cell infiltration.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        },
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C03",
      "claim": "mRNA vaccination increases PD-L1 expression in tumor tissue, making the checkpoint axis more targetable and creating a biological rationale for combination with anti-PD-L1 therapy.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable",
          "line_ref": "L32"
        },
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        }
      ],
      "caveat": "Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation from the retrospective human data."
    },
    {
      "claim_id": "C04",
      "claim": "Patients with prior SARS-CoV-2 mRNA vaccination showed improved survival under ICI treatment compared to unvaccinated patients in retrospective analysis.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "The retrospective design means residual confounding is likely, vaccination timing relative to ICI initiation varied across patients, and tumor-type heterogeneity limits causal inference."
    },
    {
      "claim_id": "C05",
      "claim": "The combination of intratumoral mRNA vaccination with anti-PD-L1 checkpoint blockade improves tumor control in preclinical models.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.",
          "line_ref": "L19"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors, and prospective randomized studies are required before clinical protocol changes are justified."
    }
  ]
}
